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ABSTRACT
Maintenance of mitochondrial gene expression is
crucial for cellular homeostasis. Stress conditions
may lead to a temporary reduction of mitochondrial
genome copy number, raising the risk of insufficient
expression of mitochondrial encoded genes. Little
is known how compensatory mechanisms operate
to maintain proper mitochondrial transcripts levels
upon disturbed transcription and which proteins are
involved in them. Here we performed a quantitative
proteomic screen to search for proteins that sustain
expression of mtDNA under stress conditions. Anal-
ysis of stress-induced changes of the human mito-
chondrial proteome led to the identification of several
proteins with poorly defined functions among which
we focused on C6orf203, which we named MTRES1
(Mitochondrial Transcription Rescue Factor 1). We
found that the level of MTRES1 is elevated in cells
under stress and we show that this upregulation of
MTRES1 prevents mitochondrial transcript loss un-
der perturbed mitochondrial gene expression. This
protective effect depends on the RNA binding ac-
tivity of MTRES1. Functional analysis revealed that
MTRES1 associates with mitochondrial RNA poly-
merase POLRMT and acts by increasing mitochon-
drial transcription, without changing the stability of
mitochondrial RNAs. We propose that MTRES1 is an
example of a protein that protects the cell from mito-
chondrial RNA loss during stress.
INTRODUCTION
Mitochondria play an important role in cell homeosta-
sis and their dysfunction is associated with numerous
pathological states in humans (1). Proper function of
these organelles depends on two separate genomes, nuclear
and mitochondrial. Although the mitochondrial genome
(mtDNA) is distinctly smaller than its nuclear counterpart,
all mtDNA-encoded proteins are essential for humans (2).
The vast majority of mitochondrial proteins are nuclear-
encoded and are imported into mitochondria after syn-
thesis in the cytoplasm (3). The mitochondrial proteome
comprises over 1500 proteins (3,4); among them are pro-
teins essential for mtDNA replication, transcription, RNA
stability and turnover, post-transcriptional modifications
and mitochondrial translation (5). The advent of mass-
spectrometry-based methods enabled advanced studies of
organellar proteomes in different cells, tissues and under
various conditions (6–10). Nevertheless, the biochemical
function of around 25% of mitochondrial proteins has yet
to be defined (11).
The human mitochondrial genome is a circular 16-kb
DNAmolecule composed of heavy (H-strand) and light (L-
strand) strands, which are distinguished by the distribution
of guanines and differential sedimentation in ultracentrifu-
gation gradients (12). MtDNA encodes 2 rRNAs, 22 tR-
NAs and 13 polypeptides, most of which are transcribed
from the H-strand. RNA synthesis from the L-strand com-
prises only one protein-coding gene and 8 tRNAs and
results mostly in non-coding antisense RNAs. Transcrip-
tion of both mtDNA strands is initiated within a non-
coding regulatory region (NCR) and spans almost the en-
tire genome (2,12). As a result, polycistronic transcripts are
formed that are further processed to produce mature func-
tional RNA molecules (13,14). The mitochondrial tran-
scription machinery appears to be simple, composed of a
monomeric RNA polymerase, POLRMT and only a few
known co-factors: TFAM, TFB2M and TEFM (2,15). In-
terestingly, the levels of mitochondrial RNAs are not nec-
essarily correlated with the copy number of mtDNA (16).
Moreover, upregulation ofmitochondrial transcription pre-
cedes replication of mtDNA when cells recover from tran-
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sient depletion of the mitochondrial genome (17).While the
basics of mitochondrial transcription have been established
(15), it is largely unknown how mitochondrial gene expres-
sion responds to conditions in which mtDNA copy number
is transiently reduced or transcription of mtDNA is ham-
pered by stressors.
Several approaches have been applied to unravel the
mechanisms of RNA metabolism in human mitochondria
(11,18–21) yet our understanding of mitochondrial gene ex-
pression is still far from complete (22). Here we applied
quantitative proteomic screening to identify new proteins
whose levels are differentially regulated in response to per-
turbed mitochondrial gene expression. Analysis of the mi-
tochondrial proteomes of human cells deprived of mtDNA
has been reported (23); however, this data presents a static
picture of mtDNA-depleted cells that have adapted to this
situation during many years of culture.
In the present study we examined changes occur-
ring upon transient mtDNA depletion and found the
novel mitochondrial regulator C6orf203, which we named
MTRES1. Our quantitative proteomic approach showed
thatMTRES1 is upregulated upon disruption of mitochon-
drial nucleic acid synthesis. We confirmed the mitochon-
drial localization of MTRES1 and showed that MTRES1
restores mtRNAs levels in stress conditions. Our data indi-
cates that MTRES1 acts at the transcriptional level with-
out influencing the stability of mitochondrial transcripts.
The protective function of MTRES1 stems from its RNA-
binding activity, which identifies this protein as a novel
validated mitochondrial RBP. We report that MTRES1 is
important for the transcriptomic output of the NCR of
mtDNA and propose that upregulation of MTRES1 upon
inhibition of mitochondrial nucleic acid synthesis acts as a
compensatory mechanism to rescue diminished mitochon-
drial transcription.
MATERIALS AND METHODS
Cell lines, cell culture and DNA cloning
Cells were cultured in Dulbecco’s-modified Eagle’s medium
(DMEM) medium (Gibco) supplemented with 10% FBS
(Gibco) at 37◦C under 5% CO2. Expression of the trans-
genes was induced with tetracycline (100 ng/ml). The 293
Flp-In T-REx cells (R78007, Thermo Fisher Scientific) or
derivative stably transfected cell lines were used. Stable
cell lines were obtained as previously described (24). DNA
cloning was performed with the help of sequence and lig-
ation independent strategy using procedures which we de-
scribed in details elsewhere (24). All DNA constructs used
for establishing stable cell lines are listed in Supplementary
Table S2.
BrU labeling and single-cell resolution fluorescence mi-
croscopy
Cells were plated on 384-well microplates (781946, Greiner,
Bio-One) and expression of the transgene was induced
with tetracycline (100 ng/ml) for 48 h before treatment
with transcription inhibitors. Cell seeding as well as fur-
ther manipulations were performed with the use of the
Multidrop Combi Reagent Dispenser (Thermo Fisher Sci-
entific). Wash steps were performed with the 405 LS Mi-
croplate Washer (Bio Tek). Transcription inhibitors were
added to the medium (time and concentration of the
reagents as indicated on Figure 4D and E) and after the in-
dicated incubation time 5-Bromouridine solution (Sigma,
final concentration of 2.5 mM), containing (or not) in-
hibitors diluted to their final concentration in the well, was
added for 1 h. Inhibitors treatment as well as BrU labeling
was performed at 37◦C under 5%CO2. Cells were then fixed
by the addition of the fixing solution to the final concentra-
tion: 5% (v/v) formaldehyde, 0.25% (w/v) Triton X-100, 2
ng/ml Hoechst 33342 in phosphate-buffered saline (PBS)
for 30 min at room temperature followed by washing four
times with PBS and blocking (3% (w/v) bovine serum al-
bumin in PBS) for 30 min. Cells were incubated overnight
at 4◦C with anti-BrdU antibodies (ab6326, Abcam) diluted
1:600 with the blocking solution. Cells were washed four
times with PBS and secondary antibodies conjugated with
Alexa Fluor 555 at 1:800 in the blocking solution were ap-
plied for 1 h followed by washing with PBS. Cells were kept
in PBS for imaging. Data were collected using ScanR fluo-
rescence microscopy system (Olympus, UPlanSApo 20.0×
objective). Image analysis was performed using ScanR 2.7.2
analysis software (Olympus). Mitochondrial transcription
was quantified. This was achieved by staining cells with
Hoechst 33342 to stain nuclei, determine their position and
area within the cell. Moreover, mitochondria were stained
to control co-localization of BrU-labeled RNAs with these
organelles. In post-imaging data analysis virtual channels
were created for BrU and nuclei, and background was sub-
tracted. An object mask was created for the nuclei and it
was excluded for the BrU spots quantification. Mean fluo-
rescent intensity of remaining (mitochondria-overlapping)
BrU-spots per cell was calculated.
Mitochondria isolation
Mitochondria isolation was performed as described previ-
ously (25) with minor modifications. Cells were centrifuged
at 400 × g for 8 min at 4◦C after harvesting from the plate
in NKM buffer (1 mM Tris–HCl, pH 7.4, 0.13 M NaCl, 5
mMKCl, 7.5mMMgCl2). Following centrifugation and re-
suspention of the pellet in ice-cold homogenization buffer
(4 mM Tris-HCl, pH 7.8, 2.5 mM NaCl, 0.5 mM MgCl2)
ten strokes of a tight-fitting pestle (Dounce homogenizer)
were applied to homogenize the cells. Nuclei and cell debris
were pelleted by two centrifugations at 900 × g for 4 min
at 4◦C. Mitochondria were pelleted by centrifugation at 10
000× g for 2 min at 4◦C. In case of the highly purified mito-
chondria preparation, the following steps were performed:
mitochondrial pellet was resuspended in H buffer (225 mM
mannitol, 75 mM sucrose, 10 mM HEPES-NaOH pH 7.8,
10 mM ethylenediaminetetraacetic acid (EDTA)) and cen-
trifuged at 10 000 × g for 2 min at 4◦C. Pellets were resus-
pended in H buffer and ultracentrifugation in 1M/1.5M su-
crose gradient was performed at 45 000 × g for 1 h at 4◦C
(WH ultracentrifuge Sorvall ThermoFisher Scientific, TH-
641 rotor). Purified mitochondria were collected from the
interphase, washed twice with H buffer and pelleted by cen-
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Mitoplasts preparation
Isolated mitochondria were resuspended in HomB buffer
(40 mMTris–HCl pH 7.6, 25 mMNaCl, 5 mMMgCl2) and
lysed with 1% Triton X-100 or incubated with 0.1% Digi-
tonin (D5628, Sigma) for 10 min on ice. Afterward, samples
were centrifuged at 7000× g for 2.5 min at 4◦C. Pellets were
resuspended in HomB buffer with or without 0.1 mg/ml
Proteinase K (EO0491, ThermoFisher Scientific) followed
by incubation on ice for 20 min. Proteinase K-treated sam-
ples were centrifuged at 7000× g for 2.5 min at 4◦C and pel-
lets were resuspended in HomB buffer supplemented with
2 mM PMSF to inhibit proteinase K. Intact mitochondria
andmitoplasts were pelleted and lysed in HomB buffer sup-
plemented with 1% Triton X-100, 2 mM PMSF and a pro-
tease inhibitor cocktail (Roche). Equal amounts of each
lysate were subjected to western blot analysis.
EtBr treatment and mass spectrometry
Cells were cultured in DMEM medium (Gibco) supple-
mented with 10% FBS (Gibco), 1 mM sodium pyruvate
(Sigma) and 50 g/l uridine (Sigma) and treated (or not)
with ethidium bromide (100 ng/ml) for 72 h. Afterward
highly purified mitochondria were isolated as described in
the ‘mitochondria isolation’ paragraph. Lysis buffer (25
mM HEPES, 2% sodium dodecyl sulphate, protease and
phosphatase inhibitors) was added to the isolated mito-
chondria. Samples were heated at 96◦C for 3 min, cooled
down, sonicated (20 cycles: 30 s on/30 s off) and heated
again for 3 min at 96◦C. Protein concentration was deter-
mined using DirectDetect Spectrometer (MerckMillipore).
Appropriate volumes containing accordingly 75 g of pro-
tein were moved to 1.5 ml tubes and precipitated using the
chloroform/methanol protocol (26): proteins were mixed
with four volumes of methanol, briefly vortexed and mixed
with one volume of chloroform, after which samples were
briefly vortexed and three volumes of water were added. Af-
ter vortexing samples were centrifuged for 2 min at 14 000
× g at 22◦C. The aqueous phase was discarded and four
volumes of methanol were added. Samples were briefly vor-
texed and centrifuged for 3 min at 14 000 × g at 22◦C. The
supernatant was discarded and the pellet was dried at room
temperature. Samples were then labeled using the stan-
dard iTRAQ 8-plex (SCIEX) protocol according to man-
ufacturer recommendations. Labeled peptide mixture was
speed-vaced to dry and then dissolved in 400 l of a buffer
containing 30% acetonitrile (ACN) and 0.1% trifluoroacetic
acid (TFA). Solution was pre-separated on a Superdex Pep-
tide 10/300 GL column, 30 min long isocratic gradient
of 30% ACN 0.1% TFA, flow 0.6 ml/min, fractions were
collected at 800 l each. Three consecutive fractions were
pooled into one and speed-vaced to dry. MS analysis was
performed by LC-MS in the Laboratory ofMass Spectrom-
etry (IBB PAS, Warsaw) using a nanoAcquity UPLC sys-
tem (Waters) coupled to an LTQ-Orbitrap QExactive mass
spectrometer (Thermo Fisher Scientific). The mass spec-
trometer was operated in the data-dependent MS2 mode,
and data were acquired in the m/z range of 100–2000. Pep-
tides were separated by a 300 min linear gradient of 95%
solution A (0.1% formic acid in water) to 45% solution B
(ACN and 0.1% formic acid). The measurement of each
sample was preceded by three washing runs to avoid cross-
contamination. Obtained data were analyzed with theMax-
Quant platform. The human reference proteome database
from UniProt was used. The following modifications were
set: oxidation(M), methylthio(C). Results were analyzed us-
ing the Scaffold 4 platform (Proteome Software).
RNA isolation and northern blot
RNA was isolated with the use of TRI Reagent accord-
ing to the manufacturer’s instructions. Northern blot was
performed according to standard protocol described else-
where (25). Shortly, 1 g of RNA was run on an agarose
gel followed by overnight capillary transfer to Hybond-
N membrane (GE Healthcare). DecaLabel DNA Labeling
Kit (Thermo Fisher Scientific) was used to radioactively
label probes with [-32P] dATP (Hartmann Analytic). In
case of strand-specific hybridizations (Figure 5), in vitro
transcription was performed utilizing polymerase chain re-
action (PCR) products containing S6 or T7 promoter se-
quence (one on each end) as a template. Primers used to
generate PCR products applied as templates for obtaining
radiolabeled probes are listed in Supplementary Table S3.
Results were recorded after overnight exposure to Phospho-
rImager screens (FujiFilm) using Typhoon FLA 9000 scan-
ner (GE Healthcare). Quantification was performed using
Multi Gauge V3.0 software (Fujifilm).
Western blot
Protein extracts were prepared and processed as previously
described (25). Primary antibodies used in this work are
listed is Supplementary Table S4. Appropriate secondary
antibodies conjugatedwith horseradish peroxidase were ap-
plied diluted 1:10 000 (401393, 401215, Calbiochem and
A5420, Sigma).
Immunoprecipitation
For immunoprecipitation (IP), 293 parental cells and cell
lines stably expressing mitochondrially targeted EGFP
(mitoEGFP) and C-terminally EGFP-tagged MTRES1
(MTRES1-EGFP) were used. In both stable cell lines
EGFP sequence is preceded with TEV protease recogni-
tion site (mito-TEV-EGFP, MTRES1-TEV-EGFP) thus
the tag can be cleaved off by TEV treatment releasing rest
of the fusion protein. This approach is described in detail
in Szczesny et al. (24). Expression of the transgenes was in-
duced with tetracycline (100 ng/ml) for 48 h before treat-
ment with EtBr. Cells were treated (or not) with EtBr (100
ng/ml) for 24 h. Afterward, mitochondria were isolated as
described in ‘mitochondria isolation’ section. Lysis buffer
(50 mM Tris–HCl pH 8.0, 100 mM NaCl, 1% Triton X-
100 (v/v) supplemented with protease and phosphatase in-
hibitors) was added to the isolated mitochondria. Samples
were incubated with rotation at 4◦C for 10 min followed by
sonication (20 cycles: 15 s on/45 s off) and centrifugation for
10 min at 12 000 × g at 4◦C. For RNase A treatment, sam-
ples were divided into two equal fractions before sonication
and one fraction was supplemented with RNase A (Sigma)
to final concentration of 20 g/ml. Supernatant was col-
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were added followed by incubation with rotation at 4◦C for
60 min. Beads were collected on the magnetic stand and
washed three times with wash buffer (50 mM Tris–HCl pH
8.0, 100 mM NaCl). Elution was performed by addition of
TEV protease in TEV buffer (50 mM Tris–HCl pH 8.0, 150
mM NaCl, 0.1% Triton X-100 (v/v)) and incubated for 90
min at room temperature. Elution was collected by discard-
ing beads on the magnetic stand.
DSP crosslinking
DSP (dithiobis[succinimidylpropionate], Thermo Fisher
Scientific) was dissolved in DMSO (dimethyl sulfoxide,
Sigma) shortly before the experiments were carried out.
Cells were harvested and suspended in PBS followed by the
addition of DSP to final concentration of 0.5 mM. Cells
were incubated with rotation at 4◦C for 30 min. Crosslink-
ing was quenched by addition of Tris–HCl pH 7.4 to 50mM
and incubation with rotation at 4◦C for 15 min. Then, sam-
ples were centrifuged at 700 × g at 4◦C followed by mito-
chondria isolation and IP as described in the ‘IP’ paragraph.
In vitro transcription and radiolabeling
In vitro transcription was performed with the use of T7
Transcription Kit (ThermoScientific) according to manu-
facturer’s instructions with the addition of [-32P] UTP
(Hartmann Analytic). As a template for in vitro transcrip-
tion, PCR products containing SP6 or T7 promoter se-
quence (one on each end) were used. Primers used in the
study are listed in Supplementary Table S3. DNA template
was removed by DNase I digestion and obtained radiola-
beled transcripts were purified on the spin columns with the
use of Sephadex G-50 gel filtration medium (GE Health-
care).
Library preparation and next-generation sequencing
RNA-seq experiment was performed in triplicate according
to the protocol described previously (24) except for the use
of a Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat,
Illumina) for rRNA removal and the use of CutSmart
buffer (New England BioLabs) for digestion with USER
Enzyme (New England BioLabs). Sequencing was carried
out on an Illumina NextSeq 500 sequencing platform, us-
ing a NextSeq 500 High Output Kit (150 cycles) (FC-404-
1002, Illumina) and pair-end sequencing procedures of 2 ×
75 cycles (Instructions: 15048776 Rev. D, 15046563 Rev. F).
Analysis of next-generation sequencing data
RNAseq raw data were preprocessed with FastQC v 0.11.3
and trimmed of adapters using cutadapt v 1.9.2.dev0. Low-
quality bases and improperly paired reads were removed
prior to mapping using Trimmomatic v 0.32. Trimmed
reads were mapped to the human genome (GRCh38) us-
ing the STAR aligner v 2.5.2b with soft-clipping allowed
(default type of alignment) and the basic GENECODE
v26 annotation with introduced features that allowed for
the quantification of all reads mapped in the D-loop re-
gion. Mapped reads were counted using htseq-count v 0.9.1
and normalized in the edgeR package v 3.18.1. Wiggle
files of uniquely mapped reads were converted to the Big-
Wig format with the use of wigToBigWig package. Tracks
of mapped reads were displayed using the Integrative Ge-
nomics Viewer (IGV) and, for the purpose of preparing
a figure, assembled using graphical software (CorelDraw).
Gene silencing efficiency was examined by calculating the
ratio of MTRES1 gene expression fold change in reference
to the parental 293 sample and by visual inspection of IGV
gene track against the adequate MTRES1 variant (Tran-
script ID ENST00000311381.7, RefSeq NM 016487).
Conserved domain search, sequence alignment and structure
representation
Conserved domain searchwas performedwith the use of the
CD-Search tool (27). Protein sequence alignment was per-
formed with the use of Clustal 2.1 program (28). Structure
representation was prepared using PyMOL software.
Protein purification
MTRES1 (86–240 aa, UniProt ID: Q9P0P8) was expressed
as a C-terminal 6xHis fusion protein. N-terminal trunca-
tion was designed according to Edman sequencing results
indicating the mature form of MTRES1 protein. Point mu-
tations (R143A, D145A, K149A, R156A, K157A) were
introduced using a standard site-directed mutagenesis ap-
proach. An E. coli BL21 strain was transformed with plas-
mids listed in Supplementary Table S2 for protein expres-
sion. Bacteria were cultured for 48 h at 18◦C in an auto in-
duction Super Broth Base (Formedium) supplemented with
kanamycin (50 g/ml). Bacteria were pelleted, homoge-
nized in the EmulsiFlex (Avestin) apparatus and obtained
extracts were subjected to purification. As a first step, pro-
teins were purified by Ni affinity chromatography followed
by gel filtration. The second round of purification encom-
passed ion exchange chromatography which was performed
with the use of a 6 ml Resource Q column (GEHealthcare).
Both steps were performed with the use of the A¨KTA ex-
press apparatus.
Electrophoretic mobility shift assay
Radiolabeled RNA substrate was prepared as described
in the ‘In vitro transcription and radiolabeling’ sec-
tion. Obtained substrates were purified by polyacrylamide
gel electrophoresis. EMSA assays were performed using
radioactive-labeled RNA at a constant concentration of 10
nM and increasing protein concentrations (up to 5 M).
Binding was performed for 30 min at 30◦C in 20 l reaction
volumes containing 10 mM Tris–HCl pH 8.0, 2.5 mMKCl,
50 mMNaCl, 1 mM EDTA, 0.5 mM dithiothreitol (DTT),
1% glycerol and 0.025%Tween-20. Afterward, 4l of Load-
ing Dye (10 mM Tris–HCl pH 7.6, 0.03% bromophenol
blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mMEDTA)
were added (R0611, Thermo Fisher Scientific) and samples
were separated in 5% polyacrylamide gel (19:1) at constant
13 W in TBE buffer (90 mM Tris, 90 mM boric acid, 2 mM
EDTA). Results were recorded using the Typhoon FLA
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the Phosphorimager screens. Quantification was performed
using Multi Gauge software (Fujifilm).
DNA isolation and qPCR
Total DNAwas isolated following a phenol–chloroform ex-
traction protocol as described previously (29). qPCR was
performed with the use of SYBR Green reagents (Roche)
according to manufacturer’s instructions. Isolated DNA
was diluted and 4 ng were used as a template in qPCR re-
actions. RSZ818 and RSZ819 starters were used to amplify
the ND1 gene, relative abundance of ND1 was normalized
to nuclear B2M gene fragment amplified with RSZ816 and
RSZ817 primers. Primers used for qPCR are listed in Sup-
plementary Table S3.
Data visualization
Graphs were prepared with the use of GraphPad Prism
version 6.00 for Windows, GraphPad Software, La Jolla,
CA, USA. Bar charts with indicated individual values pre-
sented on Figures 3 and 4 were produced using PointBar
tool (30).
RESULTS
A quantitative proteomic screen reveals proteome changes
upon mtDNA/mtRNA depletion
To search for proteins regulating mitochondrial nucleic
acids in response to perturbed mitochondrial gene expres-
sion we implemented a quantitative proteomic screen. Our
experimental strategy was based on the observation that
the level of some proteins engaged in mitochondrial nucleic
acids metabolism, including LRPPRC, SLIRP, GRSF1 and
TFAM, depends on the mtDNA/mtRNA content (17,31–
33) (Figure 1A). We assumed that other proteins, poten-
tially new mtRNA/mtDNA players, may also exhibit this
feature (Supplementary Figure S1A). To identify such pro-
teins we analyzed proteomes of highly purified mitochon-
dria from human cells with transiently reduced mitochon-
drial nucleic acids content using isobaric tag-based quan-
tification coupled with mass spectrometry (Figure 1B). We
implemented the iTRAQmethod (isobaric Tags forRelative
and Absolute Quantification) as it enables reliable quanti-
tative comparison of multiple samples (34). We treated cells
with ethidiumbromide (EtBr), a well-establishedmitochon-
drial DNA replication/transcription inhibitor (17), to in-
duce a pause in mitochondrial nucleic acid synthesis. Be-
cause diminished mitochondrial gene expression might re-
sult in disturbances of mitochondrial protein import by af-
fecting the potential of the inner membrane, we established
a cellular model based on human 293 Flp-In T-REx cells to
examine this possibility. We generated a stable 293 cell line
that expresses a fusion of EGFP with a mitochondria tar-
geting sequence derived from Cox8a protein under the con-
trol of a tetracycline-inducible promoter. Fluorescent mi-
croscopy confirmed the mitochondrial localization of the
fusion protein (Supplementary Figure S1B), indicating that
the protein can be used as a marker for mitochondrial im-
port.
To perform the screen, 293 cells expressing mitoEGFP
were treated for 3 days with EtBr and then we harvested
the cells and isolated the mitochondria. Isolated organelles
were lysed and protein extracts were subjected to iTRAQ-
based quantification (Figure 1B). Analyses of mtDNA as
well as mitochondrial transcripts levels confirmed their de-
pletion in EtBr-treated cells (Figure 1C and D). Using mass
spectrometry we identified 1381 proteins that were common
for all samples analyzed (Supplementary Table S1). The ex-
tent of mitochondrial proteome coverage observed by us
was similar to ones achieved by others (35), covering almost
60% of proteins listed inMitoCarta 2.0, which encompasses
predicted and experimentally validated mitochondrial pro-
teins (4) (Figure 1E). We identified over 90% of mitochon-
drial ribosome components (Supplementary Table S1), sug-
gesting a bias toward highly abundant proteins, an expected
feature for mass spectrometry based approaches (36). To
identify proteins whose levels depend on mtDNA/mtRNA,
we calculated the ratio of the abundance of proteins in
EtBr-treated versus untreated cells. Importantly, we found
that mitochondrial proteins (MitoCarta 2.0) were overrep-
resented among downregulated proteins as well as theywere
present in upregulated proteins (Figure 1F).
In our screen, we expected to observe a decrease in
mitochondrially-encoded proteins as well as reference pro-
teins that were described in the literature (17,32–33), which
we tested by western blot (Figure 1A). Relative changes ob-
served for these proteins guided us to set the threshold dur-
ing mass spectrometry data analysis (Figure 1G). Accord-
ingly, we identified 104 proteins as significantly downregu-
lated and 114 proteins as significantly upregulated (Figure
1G).
Gene ontology analysis of proteins whose level was
reduced upon mitochondrial nucleic acid depletion
showed a significant enrichment of proteins engaged in
mitochondria-related processes such as oxidative phos-
phorylation, respiratory electron transport chain as well
as translation (Figure 1H). Indeed, we found depletion of
mitochondrial ribosomal proteins as well as mitochondrial
and nuclear-encoded subunits of the electron transport
chain (Supplementary Table S1) upon EtBr treatment.
Notably, we did not observe changes in the level of either
mitoEGFP or HSP60 (Figure 1G). Altogether, analysis
of down-regulated proteins indicated expected changes in
the mitochondrial proteome, validating our experimental
approach.
Within the group of proteins which were significantly up-
regulated, we found proteins responsible for mitochondrial
fission/fusion processes as well as redox state regulators
(Supplementary Table S1). Interestingly we identified the
EXOG protein engaged in mtDNA repair (37) and the mi-
tochondrial DNA polymerase accessory subunit POLG2,
which is important for mtDNA maintenance (38) (Figure
1G). Upregulation of POLG2 and EXOG alongside the en-
richment of proteins involved inRNAand protein transport
and localization (Figure 1I) suggested a possible trigger
of a compensatory mechanism(s) in response to disturbed
mitochondrial gene expression. Notably, among upregu-
lated proteins we identified proteins of unknown function
in mtRNA/mtDNA metabolism. We selected four poorly
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Figure 1. Depletion of mitochondrial nucleic acids changes the mitochondrial proteome. (A) Western blot analysis of known mtRNA/mtDNA factors.
Protein lysates obtained from A549 cells with normal mtDNA content as well as cells lacking mitochondrial DNA (rho0) were analyzed. PonceauS
serves as a loading control. HSP60 represents a mitochondrial protein whose level is independent from mitochondrial nucleic acid content. (B) Schematic
representation of the experimental workflow. Cells were treated with ethidium bromide (EtBr) to inducemitochondrial nucleic acid depletion. Proteins were
extracted frommitochondria and subjected to iTRAQ labeling.Mixed labeled peptides were analyzed by liquid chromatography tandemmass spectrometry.
(C andD) Before mitochondria isolation, a fraction of EtBr-treated and untreated cells was collected for total DNA and RNA isolation. mtDNA level was
measured by qPCR (C) whereas mitochondrial transcripts were analyzed by northern blot (D). Results for individual experiments are shown. (E) Venn
diagram showing overlap between all proteins identified in the course of iTRAQ experiment and proteins present in human MitoCarta 2.0. Statistical
significance of the overlap is presented. (F) Density plot visualizing distribution of proteins identified and quantified in iTRAQ experiment in reference to
their relative abundance changes (treated/untreated). Kolmogorow–Smirnov test was applied to test equality of the distributions. Statistical significance
is presented. (G) Volcano plot of the proteins quantified in the course of the iTRAQ experiment. Each point represents a protein, protein’s fold change in
abundance is plotted against statistical significance (P-value). Continuous line determines proteins whose expression was significantly altered with FDR<
0.05 and fold-change s0> 0.2. Proteins mentioned in the text are colored blue. Mitochondrially encoded proteins are colored green. (H and I) GO analysis
of significantly down- (H) an up- (I) regulated proteins. Biological process terms enriched in this group of identifications are ranked based on fold change
with FDR< 0.05. (J) Confirmation of iTRAQ results with western blot analysis. Lysates of untreated and treated (EtBr) cells were analyzed. Image shows
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C6orf203 (renamedMTRES1) for bioinformatic analysis of
conserved domains and subcellular localization prediction.
As a result, we focused on the MTRES1 protein. Impor-
tantly, an increased level of this protein upon EtBr treat-
ment was independently confirmed by western blot analysis
of protein lysates from three additional independent exper-
iments (Figure 1J), which prompted us to study MTRES1
further as a potential factor engaged in response to per-
turbed mitochondrial gene expression.
MTRES1 is a novel mitochondrial RNA-binding protein
Our proteomic analysis of purified mitochondria suggested
that MTRES1 is a mitochondrial protein, a conclusion fur-
ther strengthened by the fluorescence microscopy analysis
of 293 cells expressing MTRES1-EGFP (Figure 2A). This
analysis showed that the fluorescent MTRES1-EGFP fu-
sion colocalizes with a mitochondria-specific dye (Figure
2A). To see if MTRES1 can be directly involved in the
mtRNA/mtDNA metabolism we tested if the protein is lo-
calized in the mitochondrial matrix, where mitochondrial
nucleic acids transactions take place. To study the submi-
tochondrial localization of the endogenous MTRES1, we
isolated mitochondria from 293 cells, prepared mitoplasts
by removing the mitochondrial outer membrane with digi-
tonin and subjected them (or not) to proteinaseK treatment
(Figure 2B). As a marker of successful mitoplast prepara-
tion we monitored the integrity of the mitochondrial inner
membrane protein OXA1L whose N-terminal part is ex-
posed to the intermembrane space, thus being susceptible to
proteinase K degradation upon outer membrane disruption
(39). While OXA1L was highly degraded by proteinase K
in digitonin-treated mitochondria, a known mitochondrial
matrix protein LRPPRC (40) remained intact, similarly to
MTRES1 (Figure 2B). This led us to the conclusion that
MTRES1 is a mitochondrial matrix protein.
A sequence search of MTRES1 against the Conserved
Domain Database (27) suggested the presence of an S4
RNA-binding domain (Figure 2C). In bacteria S4 proteins
play an important role in ribosome biogenesis where they
initiate ribosome assembly by organizing rRNA structure
and enabling successive ribosomal proteins to bind rRNA
(41). In human cells, S4 protein is a constituent of the cy-
toplasmic small ribosome subunit but is postulated to be
absent from the mammalian mitochondrial ribosome (42–
44). In line with these findings, we did not observe co-IP
of mitochondrial ribosome proteins with MTRES1-EGFP
(Supplementary Figure S2). Nevertheless, it was possible
that MTRES1 has another function that involves putative
RNA-binding ability.
Therefore, we sought to investigate if MTRES1 is able to
bind RNA. We performed in vivo crosslinking and IP with
the use of an established stable cell line expressing EGFP-
taggedMTRES1 (45), which indicated thatMTRES1 binds
RNA in vivo (Supplementary Figure S3A and B). IP of
MTRES1-EGFP and analysis of co-precipitated RNAs
with the use of qPCR showed that MTRES1 binds a
broad spectrum of mitochondrial transcripts without pro-
nounced preference as compared to the well-established mi-
tochondrial RNA-binding protein LRPPRC (Supplemen-
tary Figure S3C and D). To confirm a direct interaction
of MTRES1 with RNA, we purified the protein after het-
erologous expression. To be able to do so, we first estab-
lished the N-terminus of the mature MTRES1 since most
mitochondrial matrix proteins undergo N-terminal prote-
olytic processing after import into mitochondria (46). Be-
cause in silico analysis of theMTRES1 sequencewas insuffi-
cient to unambiguously determine the processing site of the
protein (Supplementary Figure S4A), we purifiedMTRES1
from mitochondria isolated from 293 cells and subjected it
to sequencing by Edman degradation. This approach re-
vealed that the mature protein is shorter by 84 amino acids
on the N-terminus (Figure 2C and Supplementary Figure
S4A-B). Therefore, MTRES1 devoid of the N-terminal 84
amino acids was expressed in bacteria and purified by affin-
ity chromatography (Figure 2D). Multiangle light scatter-
ing (MALS) indicated that the mass of the purified pro-
tein was very similar to its theoretical mass (19.36 kDa ver-
sus 18.25 kDa), showing that the protein is a monomer. To
see if MTRES1 binds RNA directly, we performed an elec-
trophoretic mobility shift assay using in vitro transcribed
radiolabeled mitochondrial 7S RNA as a substrate and ob-
served that MTRES1 was able to bind the substrate (Figure
2E). Thus, we concluded that MTRES1 is a mitochondrial
matrix RNA-binding protein that exists in a monomeric
form.
Silencing of MTRES1 affects RNAs originating from the
non-coding regulatory region
The RNA-binding ability of MTRES1 suggested that the
protein may be involved in mtRNAmetabolism. Therefore,
we examined the effect of MTRES1 depletion on the mi-
tochondrial transcriptome using a cellular model that en-
ables tetracycline-inducible miRNA silencing of the gene in
question (Supplementary Figure S5), an approachwhichwe
applied previously to study other proteins (47,24). We ob-
tained two stable cell lines derived from human 293 Flp-In
T-Rex cells; one cell line inducibly expresses miRNAs si-
lencing the endogenous copy of MTRES1 gene (hereafter
MTRES1 silencing), while the second cell line expresses
FLAG-tagged MTRES1 containing silent mutations that
cause insensitivity to miRNA (hereafter MTRES1 res-
cue) in addition to inducibly expressingMTRES1-targeting
miRNAs. Consequently, in the former case the MTRES1
protein should be depleted whereas in the latter case the
endogenous version of MTRES1 should be depleted and
replaced by the MTRES1-FLAG protein. Silencing of
the endogenous protein was confirmed by western blot,
which showed that MTRES1 was not detectable already
after 3 days of induction with tetracycline whereas exoge-
nous MTRES1-FLAG was expressed and was resistant to
miRNA (Figure 3A).
To investigate global changes in the mitochondrial
transcriptome upon silencing of MTRES1 we performed
an RNA-seq analysis (Figure 3B and C). We prepared
strand-specific RNA-seq libraries using RNA isolated from
parental 293 cells, silencing and rescue MTRES1 cell lines
collected 3 days after induction with tetracycline. Silenc-
ing of endogenous MTRES1 was confirmed at protein and
RNA levels (Figure 3A and Supplementary Figure S6, re-
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Figure 2. MTRES1 is a mitochondrial RNA-binding protein. (A) Intracellular localization studies of MTRES1 tagged with EGFP at the C-terminus.
Nuclei and mitochondria were stained with Hoechst and MitoTracker Deep Red, respectively. Confocal microscopy was performed. Merged image shows
colocalization of MTRES1 (green) and mitochondria (magenta). Scale bar, 10 m. (B) Western blot analysis of indicated proteins in mitochondria and
mitoplasts isolated from 293 cells and treated (or not) with proteinase K. Treatment with Triton X-100 results in disruption of both mitochondrial mem-
branes whereas digitonin disrupts only the outer membrane, increasing degradation of a part of the OXA1L protein exposed to the intermembrane space.
LRPPRC serves as a mitochondrial matrix marker. (C) Schematic representation of the MTRES1 sequence. Edman degradation indicated the cleavage
site of mitochondrial targeting sequence (MTS) (see Supplementary Figure S4 for details). In silico analysis of MTRES1 primary structure revealed the
presence of an S4-like RNA binding domain. (D) Purification of mature MTRES1. Recombinant protein was purified by heterologous expression in bac-
teria. Protein marker (M), total bacterial lysate (T) and different purification steps (P1, P2) are shown. Highly purified protein (P2) was used to perform all
biophysical and biochemical analyses. (E) EMSA assay using in vitro transcribed 7S RNA substrate and increasing concentrations of purified MTRES1
protein.
MTRES1 rescue cell line resulted from the expression of the
ectopic copy of the gene (Supplementary Figure S6B).
RNA-seq analysis, including reads coverage and distri-
bution of reads mapping to mitochondrial genome, indi-
cated that MTRES1 silencing caused a reduction of the
7S RNA level originating from transcription of the NCR
while the levels of other mtDNA-encoded transcripts were
not altered (Figure 3B and D). Importantly, the effect on
NCR-transcribed RNAs was prevented by the expression
of a miRNA-insensitive form of MTRES1, confirming that
the observed decrease of 7S RNA resulted from MTRES1
silencing and not from miRNA off-targets. Northern blot
analysis showed a significant reduction of 7S RNA levels
and no effect on other examined mitochondrial transcripts
upon MTRES1 silencing, confirming results of RNA-seq
(Figure 3E). Moreover, northern blot hybridization showed
that expression of miRNA-insensitive MTRES1-FLAG re-
stored 7S RNA levels, in accord with the RNA-seq results
(Figure 3E). To see whether MTRES1 regulates 7S RNA
levels by influencing the stability of this transcript, we ex-
amined if silencing of MTRES1 impacts the degradation
rate of 7S RNA. We inhibited mitochondrial transcription
and analyzed changes in 7S RNA levels and found the same
profile of changes in 7S RNA levels in MTRES1-silenced
and control cells (Supplementary Figure S7), indicating that
MTRES1 does not contribute to regulation of 7S RNA sta-
bility but rather to production of this RNA.
Elevated levels of MTRES1 prevent stress-induced deficiency
of mitochondrial transcription
Our analyses revealed that MTRES1 silencing causes a de-
crease in the LSP-proximal transcript 7S RNA. Interest-
ingly, the 7S RNA level has been suggested to correlate






/nar/article-abstract/47/14/7502/5521788 by ABE M
arketing user on 05 February 2020
7510 Nucleic Acids Research, 2019, Vol. 47, No. 14
Figure 3. MTRES1 silencing causes downregulation of RNAs originating from the NCR. (A) Western blot analysis of parental 293 cells (293), cells with
silencedMTRES1 (MTRES1 silencing) as well as cells expressing ectopic version of FLAG-taggedMTRES1 which replaces miRNA-silenced endogenous
copy of MTRES1 (MTRES1 rescue). Anti-MTRES1 antibodies were used. Endogenous and FLAG-tagged versions of MTRES1 are indicated with the
arrows. PonceauS membrane staining serves as a loading control. (B and C) Tracks of mapped reads obtained in RNA-seq experiment. Panel C shows
zoomed-in NCR region. The experiment was performed in triplicate. A map of mitochondrial transcripts is shown. (D) Quantification of normalized
RNA-seq counts. mtRNA level relative to 293 parental cells was calculated (mean in 293 was set as 1). Mean (± SD) and individual values are shown.
(E) Confirmation of RNA-seq results with northern blot hybridization. Methylene blue staining of nuclear-encoded rRNA serves as a loading control.
Graph shows quantification of northern blot results. mtRNA level relative to 293 parental cells was calculated (mean in 293 was set as 1). Mean (± SD)
and individual values are shown.
tified MTRES1 as a protein increased in response to mito-
chondrial nucleic acids loss, we asked if upregulation of this
protein may serve as a compensatory mechanism to rescue
diminished transcription. Using a stable 293 cell line that
inducibly upregulates MTRES1 (Figure 4A), we analyzed
mtRNAs levels after treatment with EtBr, which mimicked
conditions of our initial proteomic screen; however, we ap-
plied a shorter EtBr treatment to stall transcription rather
than decrease mtDNA levels. We found that upregulation
of MTRES1 prevents EtBr-caused decrease of 7S RNA
and other tested mtRNAs (Figure 4B). This effect was not
caused by altered levels of mitochondrial RNA polymerase
POLRMT nor mitochondrial transcription initiation fac-
tor TFAM as the levels of these proteins were unaffected
by upregulation of MTRES1 (Figure 4A). Importantly, we
confirmed that the observed protective role is specific to
MTRES1 upregulation as an overexpression of mitochon-
drially targeted EGFP did not show a similar effect (Sup-
plementary Figure S8). Moreover, analysis of mtDNA lev-
els did not reveal differences between control andMTRES1
upregulating cells treated or not with EtBr (Supplementary
Figure S9), indicating that MTRES1 acts at an RNA level
and not by increasing mtDNA copy number.
To determine if MTRES1 functions at the transcrip-
tional or post-transcriptional gene expression step we ap-
plied two approaches. First, we measured mitochondrial
transcription rates under varying stress conditions, and sec-
ond, we examined decay rates of mitochondrial RNAs to
see if RNA degradation may be prevented by MTRES1
upregulation. Moreover, we also checked if the protective
role of MTRES1 on mtRNA levels is EtBr-specific or is
linked to a general response to mitochondrial transcrip-
tional stress by treating cells with low levels of three dif-
ferent transcription inhibitors: actinomycin D (ActD), 3′-
deoxyadenosine (Cordycepin) and EtBr. While ActD and
EtBr are postulated to inhibit transcription by intercala-
tion to nucleic acids and interfering with transcription ma-
chinery, Cordycepin acts as a chain terminator. Thus it
has clearly a different mode of action than the two other
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Figure 4. MTRES1 prevents mtRNAs deficiency caused by stalled mitochondrial transcription. (A) Western blot analysis of MTRES1, TFAM and POL-
RMT levels. Specific antibodies were used to detect each protein. PonceauS membrane staining serves as a loading control. (B) Northern blot analysis
of indicated mtRNAs. RNA isolated from parental 293 cells (293) or cells overexpressing MTRES1 (MTRES1 o/e) treated (or not) with EtBr was ana-
lyzed. Methylene blue staining of nuclear-encoded rRNA serves as a loading control. (C) Schematic representation of single-cell resolution fluorescence
microscopy approach. (D and E) Quantification of single-cell resolution fluorescence microscopy data. Mean intensity of mitochondrial BrU signal cor-
responding to nascent transcription events was calculated. Cells were treated for 4 (D) or 24 (E) h with indicated inhibitors. Individual values from the
replicates are shown where in each replicate n> 500 cells (D) or n> 250 cells (E) were analyzed. Graphs show mean from the replicates ± SD. A two-tailed
unpaired t-test was applied (**P < 0.001, ***P < 0.0001).
mtRNA turnover (50–52). Using those inhibitors enabled
us to examine whether MTRES1 upregulation would pre-
vent mtRNAs loss during different kinds of transcription
stress. We used 293 parental control cells and the stable 293
cell line inducibly upregulatingMTRES1. Cells were seeded
in a 384-well format and after 48 h of MTRES1 expres-
sion induction, transcription inhibitors were added to the
medium. After 4 or 24 h of treatment nascent transcripts
were labeled in vivo with bromouridine (BrU). Cells were
then fixed and BrU-labeled RNAs were detected with the
use of anti-BrU antibodies. We collected images by high-
throughput fluorescence microscopy and quantitatively an-
alyzed signals arising from nascent transcripts with a single
cell resolution (Figure 4C). Importantly, our post-imaging
data analysis allowed us to restrict the quantitative anal-
ysis to mitochondrial transcription. We found that upreg-
ulation of MTRES1 prevents transcript loss in inhibitor-
treated cells as we observed higher quantified intensities of
mitochondrial BrU-labeled RNAs in cells overexpressing
MTRES1 in comparison to parental cells (Figure 4D and
E). Markedly, we observed the same effect independently
from the transcription inhibitor used.
To examine decay rates of mitochondrial RNAs, we shut-
off mitochondrial transcription completely by the addition
of high ActD concentration (5g/l) and analyzed the de-
crease of selected L- and H- strand mitochondrial tran-
scripts by northern blot (Figure 5A). The stability of an-
alyzed mtRNAs was the same in all samples (Figure 5B),
indicating that the protective function of MTRES1 is not
connected with post-transcriptional RNAs protection.
Together these results show that the protective role of
MTRES1 is not inhibitor specific but contributes to a gen-
eral response to diminished mtDNA transcription. More-
over, they indicate that the MTRES1 protein acts at the







/nar/article-abstract/47/14/7502/5521788 by ABE M
arketing user on 05 February 2020
7512 Nucleic Acids Research, 2019, Vol. 47, No. 14
Figure 5. MTRES1 upregulation does not influence decay of mtRNAs. (A and B) Analysis of mtRNA stability. Parental 293 cells (293) or cells with
upregulated level of MTRES1 (MTRES1 o/e) were treated with ActD (5 g/l) and collected after indicated time. Levels of mitochondrial transcripts
were analyzed using northern blot (A). Four independent experiments were performed. Graphs show quantification of autoradiographs (mean ± SEM)
(B).
The molecular function of MTRES1 strictly depends on its
RNA-binding propensities
The observed transcription rescue along with the RNA-
binding ability of MTRES1 prompted us to investigate
whether the protective function of MTRES1 stems from its
RNA binding activity. To this end, we first sought to de-
sign amutated version of the proteinwith diminishedRNA-
binding activity, without compromising its overall struc-
ture. Structural studies of bacterial S4 proteins show an ex-
tensive RNA-binding surface, without pinpointing any sin-
gle mutation that would disrupt the interaction (53,54), im-
plying that disruption of RNA-binding ability of MTRES1
could require introduction of several mutations. We aligned
the MTRES1 sequence to S4 proteins, which revealed a
few highly conserved residues (Figure 6A). Next, we ex-
tracted the Escherichia coli S4 protein structure from the ri-
bosome assembly structure (PDB ID: 4YBB) and searched
for amino acids in proximity to RNA (Figure 6B). Based on
that, we selected five residues in the MTRES1 sequence for
alanine substitution (Figure 6A). The mutated protein was
purified to high homogeneity (SupplementaryFigure S10A)
and subjected to electrophoretic mobility shift assay, which
revealed significantly decreased affinity of the mutated pro-
tein toward 7S RNA substrate when compared with wild
type (Figure 6C and D). Importantly, this decrease in affin-
ity was not accompanied by overall misfolding of the mu-
tated protein asmultiangle light scattering and thermal shift
assays showed that the mutant had the same biophysical
properties as its wild-type counterpart (Supplementary Fig-
ure S10B and C). Thus, we concluded that the designed
mutant indeed mimics the loss of RNA-binding ability of
MTRES1.
We then obtained a stable 293 cell line in which endoge-
nous MTRES1 was replaced by the FLAG-tagged RNA
binding mutant protein. We confirmed the mitochondrial
localization of the mutant protein and showed that its ex-
pression level was similar to the wild-type protein (Supple-
mentary Figure S11A and B). We then checked whether the
mutant can prevent loss of mtRNAs upon inhibition of mi-
tochondrial transcription. We found that the mutated pro-
tein did not have the ability to prevent the decrease of 7S
RNA level upon EtBr treatment (Figure 6E and F). Sim-
ilarly, application of BrU labeling approach showed that
the mutant was incapable of rescuing mitochondrial tran-
scription that was challenged with EtBr treatment. Indeed,
we observed a stronger loss of BrU signal upon EtBr treat-
ment in parental or mutant upregulating cells in compari-
son to wild-type MTRES1-upregulating counterparts (Fig-
ure 6G).
These results show that elevated levels of wild-type
MTRES1 but not of the RNA-binding mutant prevent mi-
tochondrial transcription deficiency; therefore the protec-
tive role of MTRES1 involves its RNA-binding ability.
MTRES1 interacts with mitochondrial RNA polymerase and
mitochondrial transcription initiation factor TFAM
To get an insight into the mechanism of the protective func-
tion of MTRES1 we used IP of MTRES1-EGFP to an-
alyze its interaction with the mitochondrial transcription
machinery constituents: mitochondrial RNA polymerase
POLRMT and mitochondrial transcription initiation fac-
tor TFAM. We found enrichment of mitochondrial RNA
polymerase in the MTRES1 IP fraction, while TFAM was
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Figure 6. RNA-binding propensity is required for MTRES1 molecular function. (A) Sequence comparison of human MTRES1 and representative S4
proteins. Human- Homo sapiens, E coli- Escherichia coli, Haemoph- Haemophilus influenzae, Bsubtilis- Bacillus subtilis, Bstearo- Geobacillus stearother-
mophilus. Protein’s Uniprot IDs are indicated. Conserved amino acids are highlighted in violet. Amino acids indicated with the arrows were selected for
introduction of point mutations to obtain RNA-binding deficient mutant. For clarity only the region corresponding to mature MTRES1 is presented. (B)
Structural representation of E. coli S4-protein (green). Amino acids indicated with arrows in panel A are marked in yellow while the RNA molecule is
colored blue. The rendered structures originate from structure of theE. coli ribosome (PDB ID: 4YBB). (C) EMSA assay using in vitro transcribed 7S RNA
substrate. The assay was performed using increasing concentrations of purified wild-type (MTRES1 WT) or RNA-binding deficient mutant (MTRES1
MUT) protein. (D) Quantification of EMSA results. Graph shows mean from three independent experiments ± SEM. (E) Northern blot analysis of 7S
RNA levels of untreated and treated with EtBr parental 293 cells (293), cells overexpressing wild-type MTRES1 (WT) and cells overexpressing mutant
MTRES1 (MUT). Methylene blue staining of nuclear-encoded rRNA serves as a loading control. (F) Quantification of northern blot results from four
independent replicates. Relative change corresponding to 7S RNA level in untreated cells is shown. Boxes cover 25–75th percentiles. Whiskers go from
smallest to largest values. Horizontal lines represent mean values. (G) Quantification of single-cell resolution fluorescence microscopy data. Mean intensity
of mitochondrial BrU signal corresponding to nascent transcription events was calculated. Cells were treated for 4 h with EtBr. Individual values from the
replicates are shown where in each replicate n > 140 cells were analyzed. Graphs show mean from the replicates ± SD. A two-tailed unpaired t-test was
applied (**P < 0.001, ***P < 0.0001).
elution fraction as POLRMT was (Figure 7A). We ob-
servedMTRES1-POLRMT andMTRES1-TFAM interac-
tions under normal as well as stress conditions (EtBr treat-
ment). Importantly, we did not observe co-IP of POLRMT
and TFAM in parental 293 cells or in the control cell line
expressing mitochondrially targeted EGFP (mitoEGFP),
showing specificity of the identified associations. Moreover,
we did not detect highly abundant mitochondrial ribosomal
proteins to co-purify withMTRES1 in the same IP samples
(Supplementary Figure S2).
Next, we examined whether the observed interactions
are direct or are mediated by RNA. To do so, we divided
protein extracts into two equal fractions and treated one
of them with RNase A prior to IP. Co-IP of POLRMT
with MTRES1 turned out to be essentially insensitive to
RNase treatment, indicating that interactions of MTRES1
with POLRMT are not mediated by RNA (Figure 7B).
In contrast, the amount of TFAM in the elution fraction
was strongly decreased when the protein lysate was treated
withRNase before IP (Figure 7B), indicating thatMTRES1
associates with TFAM in an RNA-dependent manner. In
agreement with that MTRES1-TFAM interactions can be
stabilized and become RNase A-insensitive if cells are sub-
jected to chemical crosslinking with DSP (55) prior to cell
lysis and IP (Figure 7C) since DSP introduces covalent
bonds between proteins being in proximity.
In conclusion, MTRES1 physically interacts with POL-
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Figure 7. MTRES1 associates with mitochondrial transcription ma-
chinery. Western blot analysis of proteins co-immunoprecipitating with
MTRES1. A cell line stably expressing MTRES1-EGFP was used. As a
control parental 293 cells and/or the control cell line expressing mitochon-
drially targeted EGFP (mitoEGFP) were used. IP was performed with
GFP-Trap nanobodies (Chromotek). Anti-POLRMT and anti-TFAMan-
tibodies were used in western blot analysis. (A) Cells were treated (EtBr) or
not (NT) with 100 ng/ml EtBr for 24 h followed by preparation of protein
extracts and IP (B) Protein extracts were divided into two equal fractions
and one of them was treated with RNase A prior to IP. (C) Cells were
crosslinked with DSP prior to preparation of protein extracts. Protein ex-
tracts were divided into two equal fractions and one of them was treated
with RNase A following IP.
RNA-mediated. These results further support the conclu-
sion that MTRES1 plays its protective role at the transcrip-
tional level, classifying it asmitochondrial transcription res-
cue factor (MTRES1).
DISCUSSION
Maintenance ofmitochondrial gene expression is crucial for
cellular homeostasis. In contrast to nuclear DNA, the mi-
tochondrial genome exists in multiple copies. Expression
of mitochondrially encoded genes seems to be correlated
with mtDNA abundance (56); nevertheless, in some con-
ditions a decrease in mtDNA levels can be compensated
for at the transcriptional and/or post-transcriptional level.
This compensation allows for maintenance of mitochon-
drial function despite severe depletion of mtDNA, as in
the case of patients in whom mitochondrial disease devel-
ops late (57). Similarly, compensatory mechanism(s) act-
ing at the RNA level operate during mammalian embryo-
genesis when transcription of mtDNA precedes its repli-
cation and is concomitant with a progressive reduction in
mtDNA copies per cell (58–60). Compensation at the level
of mtRNA metabolism has also been observed in in vitro
cultured cells treated with mtDNA replication inhibitor
(16). Molecular mechanisms and proteins involved in these
compensatory pathways are largely unknown.
Here we present the results of a quantitative proteomic
screen that revealed a new RNA binding protein C6orf203
as a factor engaged in mitochondrial transcription regu-
lation upon perturbed mitochondrial gene expression. We
show that C6orf203 is able to restore diminished transcrip-
tion and that its level is upregulated upon depletion ofmito-
chondrial nucleic acids, suggesting that it acts as a compo-
nent of a compensatory mechanism that maintains proper
function of mitochondria during stress. Our data suggest
that the function of C6orf203 might be redundant during
steady-state conditions. On the contrary during transcrip-
tion arrest, C6orf203 functions as a protective factor to
maintain proper mtRNAs level, thus we renamed the pro-
tein mitochondrial transcription rescue factor (MTRES1).
MTRES1 acts at the transcription level and its protective
function depends on its RNA binding ability. We found
that MTRES1 restores mtRNAs levels in stress conditions
without influencing their stability. According to our re-
sults, MTRES1 seems not to be a stable component of
the mitochondrial ribosome, in agreement with previous re-
ports suggesting that S4 protein is absent from the human
mitochondrial ribosome (42–44). Nevertheless, we cannot
exclude the possibility that MTRES1 may transiently or
weakly associate with the mitochondrial ribosome.
MTRES1 clearly has a different impact on the mitochon-
drial transcriptome depending on the state and efficiency of
mitochondrial transcription. We found that under steady-
state conditions MTRES1 is required only for maintain-
ing a proper level of 7S RNA, while the levels of other ex-
amined mtRNAs do not depend on MTRES1. Similarly, a
screen for mtRNA processing factors performed by others
did not reveal any significant changes in the processing or
steady-state levels of coding and antisense mtRNAs (19)
upon MTRES1 silencing; 7S RNA was not examined in
the screen, precluding full comparison with our results (19).
Our data support a view that 7S RNA is a separate tran-
scriptional unit. Why its activity is affected by the knock-
down of MTRES1 under normal conditions requires fur-
ther studies. We observed that stability of 7S RNA does
not depend on MTRES1, indicating that the protein is re-
quired for production of this transcript. In reference to our
data, it seems that the impact of MTRES1 on the mito-
chondrial transcriptome is shifted to general response when
mitochondrial transcription is affected. Under these condi-
tions all examined mtRNAs benefit from the upregulation
of MTRES1 as it prevents the decrease of mtRNAs levels
by increasing mtDNA transcription.
In recent years biochemical and structural studies have
provided substantial insight into the molecular mechanism
ofmtDNA transcription. These elegant studies showed that
TFAM and TFB2M are required for the initiation of RNA
synthesis, while the elongation factor TEFM supports poly-
merase processivity (15). Nevertheless, there are still open
questions. For example, studies conducted so far did not
consider stress conditions, which we addressed in our stud-
ies. We found that the support of mitochondrial transcrip-
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Thus, it is possible thatMTRES1 improves transcription by
binding to nascent RNA when RNA polymerase is stalled.
Bacterial S4 protein was shown to increase transcription
by acting as an antitermination factor (61). The molecular
details of this mechanism are unknown but it seems likely
that it involves direct interaction of S4 protein with RNA
polymerase (61). Murine C6orf203 was shown to be up-
regulated in vivo in TFAM knockout mice (62), suggesting
functional interplay between these proteins. Indeed, we ob-
served that MTRES1 associates with TFAM in an RNA-
dependent manner, which suggests weak/transient or indi-
rect interactions. Moreover, we found that MTRES1 co-
purifies with POLRMT. Interestingly, this interaction seems
to be direct, as it is largely insensitive to RNase treatment.
Association of MTRES1 with TFAM and POLRMT may
indicate that it acts at the transcription initiation step as
TFAMand POLRMT form the pre-initiation complex (15).
Further biochemical and structural studies could test this
hypothesis.
Recently, a study combining proteomic and transcrip-
tomic approaches revealed activating transcription factor
4 (ATF4) to be a regulator of mitochondrial stress re-
sponse (63). Since the MTRES1 protein is not present in
this proteomic dataset it is not possible to assess to what
extent MTRES1 contributes to the ATF4-regulated mech-
anism. The lack of MTRES1 in the abovementioned pro-
teomic data suggests that this protein can be difficult to
identify by a mass spectrometry approach. Accordingly
in HeLa proteome MS-based studies MTRES1 sequence
coverage was at 8% which put MTRES1 in the 12 per-
centile among ∼9000 quantified proteins (64). Such bias
may explain why MTRES1 was not previously reported as
an RNA-binding protein in various MS-based approaches
(65–67). Our cross-linking and IP experiment as well as in
vitro binding assays showed the RNA binding ability of
MTRES1, as predicted based on the similarity to S4 pro-
teins. Similarly to the work of others on S4 proteins (53–54),
wewere unable to pinpoint a single residue inMTRES1 that
would be essential for interaction with RNA. Instead, we
identified a few residues whose substitutions resulted in dis-
ruption of MTRES1-RNA interactions. Importantly, the
structure of the protein was not disturbed by these substi-
tutions, confirming that the mutated residues play a role in
RNAbinding.Ourmutagenesis-based data pave theway for
a detailed exploration of MTRES1 molecular function.
Since all proteins required for mtDNA maintenance and
expression, including MTRES1, are encoded in the nucleus
(3), cross-talk between mitochondria and the nucleus is
necessary to coordinate nucleo-mitochondrial gene expres-
sion to maintain appropriate mitochondrial function (68).
The murine C6orf203 gene was reported as potentially co-
regulated in skeletal muscle (69) by PGC-1, which is a key
regulator of mitochondrial biogenesis in response to extra-
cellular signals, cell energy demand, or mitochondrial dys-
function (70). It was shown that the expression of mito-
chondrial transcription machinery components including
TFB2M and TFAM are regulated by the members of PGC-
1 family (71,72). These observations, togetherwith our data,
suggest thatMTRES1may belong to a group of factors that
adjust mtDNA expression to the cellular milieu.
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